Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study

Article Article scientifique Article Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study eng 2017 author Beguelin Charles 768398 author Friolet Nicole 782161 author Moradpour Darius author Sahli Roland 914557 author Suter-Riniker Franziska author Lüthi Alexander author Cavassini Matthias author Günthard Huldrych F author Battegay Manuel author Bernasconi Enos 663410 author Schmid Patrick 89008 author Calmy Alexandra 0000-0002-1137-6826 41032 author Atkinson Andrew author Rauch Andri author Wandeler Gilles 1275-1278 10.1093/cid/cix125 28199492 1058-4838 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years. Adult Anti-HIV Agents/therapeutic use Cohort Studies Female HIV Infections/complications/drug therapy Hepatitis B virus/isolation & purification Hepatitis B Chronic/complications/virology Hepatitis D/virology Hepatitis Delta Virus/drug effects/isolation & purification/physiology Humans Male Middle Aged Switzerland Tenofovir/therapeutic use Viral Load Virus Replication/drug effects Dewey 616 56 Département de médecine 221 false 587 VIH/SIDA 930 Clinical Infectious Diseases 64 9 a67bc5b8-4afa-4222-a790-8a322223e224 Article (Published version) Restricted 28199492_ClinInfectDis_Béguelin.pdf 909143 application/pdf restrictedAccess Faculté de médecine / Section de médecine clinique / Département de médecine

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study	Clinical Infectious Diseases			2017	402	0

Archive ouverte UNIGE

Friolet, Nicole